ロード中...
Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report
Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase (ALK) gene rearrangement, is generally well tolerated. In contrast, neutropenia induced by crizotinib is a commonly reported grade 3 or 4 adverse event. In such cases, interruption and dose reduction of crizotinib mig...
保存先:
| 出版年: | Case Rep Oncol |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
S. Karger AG
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4748772/ https://ncbi.nlm.nih.gov/pubmed/26933419 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000443662 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|